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Abstract
We determined whether phosphorylated epidermal growth factor receptor (EGFR) expressed on tumor-associated
endothelial cells is a primary target for therapy with EGFR tyrosine kinase inhibitors (TKIs). Human colon cancer
cells SW620CE2 (parental) that do not express EGFR or human epidermal growth factor receptor 2 (HER2) but
express transforming growth factor α (TGF-α) were transduced with a lentivirus carrying nontargeting small hairpin
RNA (shRNA) or TGF-α shRNA. The cell lines were implanted into the cecum of nude mice. Two weeks later, treat-
ment began with saline, 4-[R]-phenethylamino-6-[hydroxyl] phenyl-7H-pyrrolo [2,3-D]-pyrimidine (PKI166), or irinote-
can. Endothelial cells in parental and nontargeting shRNA tumors expressed phosphorylated EGFR. Therapy with
PKI166 alone or with irinotecan produced apoptosis of these endothelial cells and necrosis of the EGFR-negative
tumors. Endothelial cells in tumors that did not express TGF-α did not express EGFR, and these tumors were re-
sistant to treatment with PKI166. The response of neoplasms to EGFR antagonists has been correlated with EGFR
mutations, HER2 expression, Akt activation, and EGFR gene copy number. Our present data using colon cancer
cells that do not express EGFR or HER2 suggest that the expression of TGF-α by tumor cells leading to the acti-
vation of EGFR in tumor-associated endothelial cells is a major determinant for the susceptibility of neoplasms to
therapy by specific EGFR-TKI.
Neoplasia (2008) 10, 489–500
Introduction
The major cause of death from cancer is due to metastases that are
resistant to conventional therapies. The genetic instability of tumor
cells in general and metastatic cells in particular is responsible for
generating biologic heterogeneity in metastatic lesions which is a
major cause for the failure of systemic antitumor therapy [1,2]. Be-
cause the progressive growth and survival of all neoplasms are de-
pendent on the development of an adequate vascular supply [3],
targeting the tumor vasculature can be an effective approach for ther-
apy for primary tumors in general and metastases in particular.
Growth factors and their receptors play a central role in the pro-
gressive growth of neoplasms. Overexpression of the epidermal
growth factor receptor (EGFR) and its ligands, transforming growth
Abbreviations: EGF, epidermal growth factor; EGFR, EGF receptor; HER2, human
epidermal growth factor receptor 2; PKI166, 4-[R]-phenethylamino-6-[hydroxyl] phenyl-
7H-pyrrolo [2,3-D]-pyrimidine; shRNA, small hairpin RNA; TGF, transforming growth
factor; TKI, tyrosine kinase inhibitor
Address all correspondence to: Isaiah J. Fidler, DVM, PhD, Department of Cancer
Biology, Unit 173, The University of Texas M. D. Anderson Cancer Center, 1515
Holcombe Boulevard, Houston, TX 77030. E-mail: ifidler@mdanderson.org
1This work was supported in part by Cancer Center Support Core grant CA16672
and Specialized Programs of Research Excellence in Prostate Cancer grant CA902701
from the National Cancer Institute, National Institutes of Health.
2These authors contributed equally to this work.
Received 22 January 2008; Revised 20 February 2008; Accepted 22 February 2008
Copyright © 2008 Neoplasia Press, Inc. All rights reserved 1522-8002/08/$25.00
DOI 10.1593/neo.08200
www.neoplasia.com
Volume 10 Number 5 May 2008 pp. 489–500 489
factor α (TGF-α)/EGF by many cancers has been correlated with
poor prognosis [4–6]. Colon cancer cells secrete TGF-α in response
to hypoxia and the ligand signals, the cell surface EGFR, to initiate a
sequence of cell survival programs [7]. This activation of the EGFR
signaling pathways contributes to cell proliferation and survival by
triggering downstream signaling molecules, such as Akt and mito-
gen-activated protein kinase [8–10]. The close association between
coexpression of TGF-α/EGF and EGFR in tumor cells and stroma
cells [11–13] with resistance to chemotherapy and hence poor sur-
vival has advanced EGFR as a logical target for therapy.
Small-molecule EGFR tyrosine kinase inhibitors (TKIs) have been
studied in multiple clinical trials against relapsed non–small cell lung
cancer. However, only a small percentage of the patients responded to
EGFR antagonists given as a single agent [14–16]. Whether the sen-
sitivity to EGFR-TKI is correlated to the expression level of EGFR on
tumor cells has been controversial [17–19]. Several studies reported
that the response to EGFR-TKI is associated with specific mutation
in the tyrosine domain of EGFR [20–23] or with a high EGFR gene
copy number [17,24]. Later studies, however, indicated that mutations
in the tyrosine domain of EGFR were also found in nonresponding
tumors [18,19], suggesting that the response to therapy may be due
to other mechanisms.
We have recently reported that in multiple carcinomas, EGFR was
phosphorylated not only on tumor cells but also on tumor-associated
endothelial cells. The phosphorylation of EGFR on tumor-associated
endothelial cells, however, was only found in the vasculature of tumors
that produced TGF-α/EGF [25–27]. In nude mice implanted with
human carcinoma cells (pancreas, colon, renal, prostate, ovarian) into
the relevant orthotopic organs, treatment with specific EGFR-TKI
produced apoptosis of tumor cells and tumor-associated endothelial
cells [28]. On the basis of these findings, we hypothesized that a major
determinant for neoplastic sensitivity to EGFR-TKI is the production
of TGF-α/EGF by tumor cells and activation of EGFR on tumor-
associated endothelial cells. To test this hypothesis, we used the
SW620CE2 human colon cancer cells. These cells do not express
EGFR or human epidermal growth factor receptor 2 (HER2) but
do express TGF-α [29]. The cells were transduced with lentivirus
small hairpin RNA (shRNA) or lentivirus TGF-α shRNA. The three
different SW620CE lines were implanted into the cecal wall of nude
mice, and 2 weeks later, treatment with a specific EGFR-TKI began.
Only tumors producing TGF-α were sensitive to the therapy. Because
none of the tumor cells expressed EGFR, the data identified the EGFR
expressed by tumor-associated endothelial cells as the primary target.
Materials and Methods
Colon Cancer Cell Line and Culture Conditions
SW620 human colon cancer cells obtained from Dr. Gary Gallick,
M. D. Anderson Cancer Center [29] were maintained in minimal
essential medium supplemented with 10% fetal bovine serum, sodium
pyruvate, nonessential amino acids, L-glutamine, a two-fold vitamin
solution (Life Technologies, Grand Island, NY), and a penicillin/
streptomycin mixture (Flow Laboratories, Rockville, MD). Adherent
monolayer cultures were maintained on plastic and incubated at
37°C in a mixture of 5% CO2 and 95% air. The cultures were free
of Mycoplasma and pathogenic murine viruses (assayed by Science Ap-
plications International Co., Frederick, MD) and were maintained for
no longer than 12 weeks after recovery from frozen stocks.
In Vivo Selection of Highly Tumorigenic Variants from the
SW620 Human Colon Cancer Cell Line
SW620 cells were injected into the cecal wall of nude mice. Three
months after the injection, cecal tumors were harvested and treated
with DNase and collagenase as described previously [30]. Cells were
established in culture. Primary cultures were passaged in vitro two or
three times, and then cells were harvested by trypsinization and were
injected into the cecum of another set of nude mice. The selection cycle
was repeated twice to yield the cell line designated as SW620CE2.
Small Hairpin RNA of TGF-α and Lentivirus Production
Sense and antisense oligonucleotides from the TGF-α mRNA (Ac-
cession No. NM-003236) was designed with a hairpin and sticky ends
(ClaI andMluI) for use with the lentiviral system developed and kind-
ly provided by Didier Trono, University of Geneva, Switzerland [31].
The target sequences for TGF-α shRNA were 5′-GCATGTGT-
CTGCCATTCTG-3′ and 5′-CAGAATGGCAGACACATGC-3′.
The target sequences for nonspecific control shRNA (nontargeting
shRNA) were 5′-TAAGGCTATGAAGAGATAC-3′ and 5′-GTATC-
TCTTCATAGCCTTA-3′. We then ligated these oligos and annealed
them into the lentiviral gene transfer vector, pLVTHM, that drives
the expression of the green fluorescent protein for independent moni-
toring of transfection/infection efficiencies, using the ClaI and MluI
restriction enzyme sites. The lentivirus was then produced by trans-
fecting human embryonic kidney cells (293FT) with the sequenced-
verified pLVTHM vector, the packaging plasmid (MD2G), and
envelope plasmid (PAX2) required for viral production. Three days
later, the viral supernatant was collected and filtered to remove cel-
lular debris. SW620CE2 cells were transduced with the lentivirus
and green fluorescent protein–positive populations were enriched to
100% by fluorescence-activated cell sorting.
Reverse Transcription–Polymerase Chain Reaction
Total RNAs were isolated with RNeasy kit (Qiagen, Hilden, Ger-
many), according to the manufacturer’s recommended instructions,
and cDNAs were synthesized from 1 μg of each total RNA preparation
by use of oligo(dT) primers and reverse transcriptase (Reverse Transcrip-
tion System; Promega, San Luis Obispo, CA). We prepared appropriate
dilutions of each single-stranded cDNA for subsequent polymerase
chain reaction (PCR) amplification and monitored the reactions by
using β-actin (ACTB) as a quantitative control. The primer sequences
were 5′-CATCCACGAAACTACCTTCAACT-3′ and 5′-TCTCCTT-
AGAGAGAAGTGGGGTG-3′, for ACTB; 5′-CTGGCTGTCCT-
TATCATCAC-3′ and 5′GACGGAGTTCTTGACAGAGT-3′ for
TGF-α; 5′-TTTCGATACCCAGGACCAAGCCACAGCAGG-3′
and 5′AATATTCTTGCTGGATGCGTTTCTGTA-3′ for EGFR,
and 5′-ACATCTTCCAGGAGTACCCTGATGAG-3′ and 5′GCA-
TTCACATTTGTTGTGCTGT-3′ for vascular endothelial growth
factor A (VEGFA); 5′-CATCACATCCACTGGTATT-3′ and 5′-GC-
CAAGCTTGTACCATGTG-3′ for vascular endothelial growth factor
receptor 2 (VEGFR2). All reactions had an initial denaturation step at
94°C for 4 minutes, followed by 19 cycles (for ACTB), 28 cycles (for
TGF-α), 33 cycles (for EGFR or VEGFA), or 35 cycles (for VEGFR2)
at 94°C for 30 seconds, 55°C for 30 seconds, and 72°C for 30 seconds.
All reactions took place in a Mastercycler gradient 5331 PCR machine
(Eppendorf AG, Cologne, Germany). The PCR products were sepa-
rated by electrophoresis on 1.5% agarose gels and stained with ethidium
bromide. The experiment was performed three times.
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In Vitro Production of TGF-α
The production and secretion of TGF-α by human colon can-
cer cell lines (SW620CE2, SW620CE2 nontargeting shRNA, and
SW620CE2 TGF-α shRNA) were determined 48 hours after plating
3 × 105 cells in 0.8 ml of serum-free medium (minimal essential me-
dium) into six-well tissue culture plates. The supernatants of wells
from each plate were collected and analyzed for the level of TGF-α
using enzyme-linked immunosorbent assay (ELISA) kit from R&D
Systems (Minneapolis, MN). The concentration of TGF-α was stan-
dardized by cell number.
Western Blot Analysis
Adherent cells were washed with phosphate-buffered saline (PBS)
containing 5 mM EDTA and 1 mM sodium orthovanadate and then
scraped into lysis buffer (20 mM Tris–HCl [pH 8.0], 137 mMNaCl,
10% glycerol, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride,
20 μM leupeptin, and aprotinin at 0.15 U/ml), and the mixture
was incubated for 20 minutes on ice. The lysed cells were centrifuged
at 16,000g for 15 minutes at 4°C, and the supernatant was collected.
Proteins in the supernatant were quantified by spectrophotometry,
and a constant amount of protein was loaded per lane, resolved by
sodium dodecyl sulfate, 7.5% polyacrylamide gel electrophoresis,
and transferred to nitrocellulose membranes (pore size, 0.45 μm).
The membranes were incubated with 5% milk in Tris-buffered saline
(TBS, 20 mM Tris–HCl [pH 7.5] and 150 mM NaCl) to block
nonspecific binding and were then probed with either a rabbit anti–
human EGFR polyclonal antibody (1:2000 dilution; Santa Cruz
Biotechnology, Santa Cruz, CA) or a rabbit anti–human β-actin
(1:2000 dilution; Sigma, St. Louis, MO) in Tween-TBS (TTBS,
0.1% Tween 20 in TBS). Blots were then incubated with horseradish
peroxidase–conjugated donkey anti–rabbit IgG (1:2000 dilution;
Sigma) in TTBS. Antibody-reactive protein bands were visualized
with an enhanced chemiluminescence detection system (Amersham
Biosciences, Piscataway, NJ).
Reagents
PKI166 (4-[R]-phenethylamino-6-[hydroxyl] phenyl-7H-pyrrolo
[2,3-D]-pyrimidine), a novel and specific EGFR-TKI, was synthe-
sized and provided by Novartis Pharma (Basel, Switzerland) [32].
For in vivo administration, PKI166 was dissolved in DMSO/0.5%
Tween 80 and was then diluted 1:20 in water. Irinotecan (Camptozar;
Pharmacia, Kalamazoo, MI) was kept at room temperature and dis-
solved in 0.9% NaCl on the day of intraperitoneal (i.p.) injection.
Primary antibodies used were as follows: rabbit anti–phosphorylated
EGFR (pEGFR; Tyr1173; Biosource, Camarillo, CA); mouse anti-
EGFR (Zymed, San Francisco, CA); mouse anti–TGF-α (Oncogene,
Boston, MA) rabbit anti-EGF (Santa Cruz Biotechnology); rat anti–
mouse CD31 (BD PharMingen, San Diego, CA); and rabbit anti–
Ki-67 antigen (Vector Laboratories, Burlingame, CA) for immunohisto-
chemistry, and rabbit anti-EGFR (SC03; Santa Cruz Biotechnology)
for Western blot analysis. The following secondary antibodies were used
for colorimetric immunohistochemistry: peroxidase-conjugated goat
anti–rabbit IgG (Jackson ImmunoResearch Laboratories, Inc., West
Grove, PA); peroxidase-conjugated goat anti–mouse IgG (Jackson
ImmunoResearch Laboratories); and peroxidase-conjugated goat anti–
rat IgG (Jackson ImmunoResearch Laboratories). The following fluo-
rescent secondary antibodies were used: Cy3-conjugated goat anti–
rabbit IgG; Cy3-conjugated goat anti–mouse IgG; Cy3-conjugated goat
anti–rat IgG; and Cy5-conjugated goat anti–rat IgG (all obtained from
Jackson ImmunoResearch Laboratories). The following secondary anti-
bodies were used for Western blot analysis: peroxidase-conjugated goat
anti–rabbit IgG (Jackson ImmunoResearch Laboratories). Terminal
deoxynucleotidyl transferase–mediated nick end labeling (TUNEL)
staining was done using a commercial apoptosis detection kit (Promega,
Madison, WI) with modifications.
Animals and Orthotopic Implantation of Tumor Cells
Male athymic nude mice (NCI-nu) were purchased from the Ani-
mal Production Area of the National Cancer Institute Frederick
Cancer Research and Development Center (Frederick, MD). The
mice were housed and maintained under specific pathogen-free con-
ditions in facilities approved by the American Association for Ac-
creditation of Laboratory Animal Care and in accordance with
current regulations and standards of the US Department of Agricul-
ture, the US Department of Health and Human Services, and the
National Institutes of Health. The mice were used in accordance
with institutional guidelines when they were 8 to 12 weeks old.
To produce cecal tumors, SW620CE2 WT, SW620CE2 non-
targeting shRNA, and SW620CE2 TGF-α shRNA cells were
harvested from subconfluent cultures by a brief exposure to 0.25%
trypsin and 0.02% EDTA. Trypsinization was stopped with medium
containing 10% fetal bovine serum, and the cells were then washed
once in serum-free medium and resuspended in Hanks’ balanced salt
solution. Only suspensions consisting of single cells with >90% via-
bility were used. A total of 5 × 105 cells in 50 μl of Hanks’ balanced
salt solution were injected into the cecal wall of nude mice under a
dissecting microscope as described previously [27].
Treatment of Established Human Colon Carcinomas Growing
in the Cecum of Athymic Nude Mice
Fourteen days after injection of tumor cells when cecal tumors
reached the size of 4 to 5 mm in diameter, groups of 10 mice each
were randomly assigned to receive one of the following four treat-
ments: 1) oral administration of water diluted at 1:20 with DMSO–
0.5% Tween 80 (diluent) three times per week and i.p. injection of
PBS once a week (control group); 2) oral administration of PKI166
(100 mg/kg) three times per week and i.p. injection of PBS once a
week; 3) oral administration of diluent by three times per week and
i.p. injection of irinotecan (10 mg/kg) once a week; and 4) combina-
tion of oral PKI166 (100 mg/kg) three times per week and i.p. injec-
tion of irinotecan (10 mg/kg) once a week. All treatments were carried
out for 5 weeks.
Necropsy Procedures and Histologic Studies
The mice were euthanized by methoxyflurane, and their body
weight was recorded. On necropsy, tumors growing in the cecum
and peritoneum were excised and weighed. For immunohistochemi-
cal and hematoxylin and eosin staining procedures, one part of the
tumor tissue was fixed in formalin and embedded in paraffin and
another was embedded in optimal cutting temperature compound
(Miles, Elkhart, IN), rapidly frozen in liquid nitrogen, and stored
at −80°C. All macroscopically enlarged mesenteric lymph nodes were
harvested, and the presence of metastatic disease was confirmed by
histologic examination.
Immunohistochemical Staining for TGF-α and EGF
Paraffin-embedded tissues were used for immunohistochemical
analyses of TGF-α and EGF. The sections were deparaffinized
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in xylene, dehydrated with alcohol, and rehydrated in PBS. Endoge-
nous peroxidase was blocked with 3% hydrogen peroxide in PBS.
The slides were placed in a humidified chamber and incubated with
protein blocking solution (5% normal horse serum and 1% normal
goat serum in PBS) for 20 minutes at room temperature and incu-
bated overnight at 4°C with primary antibody against TGF-α
(1:100) and EGF (1:100). For TGF-α staining, the slides were
incubated overnight at 4°C with goat anti–mouse IgG, Fab fragment
(Jackson ImmunoResearch Laboratories) to block endogenous im-
munoglobulins, followed by incubation with the primary antibody.
Slides were washed with PBS three times, incubated with peroxidase-
conjugated secondary antibody (1:500) for 1 hour, and then positive
reaction was detected by exposure to stable 3,3′-diaminobenzidine
(Phoenix Biotechnologies, Huntsville, AL). The slides were counter-
stained with Gill’s no. 3 hematoxylin. Sections stained for immuno-
peroxidase or hematoxylin and eosin were examined in a fluorescence
microscope (Microphot-FX; Nikon Instruments, Inc., Melville, NY)
equipped with a three-chip charged coupled device color video cam-
era (Model DXC990; Sony Corp., Tokyo, Japan). Digital images
were captured using Optimas Image Analysis software (Media Cyber-
netics, Silver Spring, MD).
Double Immunofluorescence Staining for EGFR or pEGFR
and CD31 in Tumor Tissues
Frozen sections of cecal tumors from nude mice were cut into
4-μm sections, mounted on positively charged slides, and stored at
−80°C. Slides were fixed in cold acetone for 10 minutes, placed in
a light-shielded humidified chamber, incubated with protein block-
ing solution (5% normal horse serum and 1% normal goat serum
in PBS) for 20 minutes at room temperature, and incubated over-
night at 4°C with primary antibody against EGFR (1:200) or
pEGFR (1:100). For EGFR staining, the slides were incubated over-
night at 4°C with goat anti–mouse IgG, Fab fragment (Jackson
ImmunoResearch Laboratories) to block endogenous immunoglobu-
lins, followed by incubation with the primary antibody. The slides
were washed with PBS three times and then incubated for 1 hour
at room temperature with goat anti–mouse or –rabbit Cy3 secondary
antibody (1:500). Then, the slides were incubated overnight at 4°C
with an antibody against CD31 (1:800). The slides were washed
with PBS three times and then incubated for 1 hour at room tem-
perature with goat anti–rat Cy5 secondary antibody (1:500). Nuclear
counterstain with Sytox green was applied for 10 minutes, and a
mounting medium (90% glycerol, 10% PBS, and 0.1 M propyl gal-
late) was placed on each sample, which were then covered with a glass
coverslip (Fischer Scientific, Pittsburgh, PA). Endothelial cells (CD31-
positive cells) were identified by green fluorescence, whereas EGFR- or
pEGFR-positive cells were identified by red fluorescence. The presence
of EGFR or pEGFR on endothelial cells was detected by colocalization
of red and green fluorescence, which appeared yellow.
Immunohistochemical Determination of Ki-67 Antigen,
CD31, and TUNEL
Paraffin-embedded tissues were used for immunohistochemical
staining for Ki-67 as previously described [33]. Ki-67 labeling index
(LI) was determined by light microscopy at the site of the greatest
number of Ki-67–positive cells. The representative areas were deter-
mined by scanning tumor sections using low power (magnification,
×40). For Ki-67 LI, the number of positive cells among approxi-
mately 1000 tumor cells was calculated as a percentage. Frozen tis-
sues were used for quantifying mean vessel density (MVD). Frozen
sections were fixed in cold acetone (10 minutes), and immunohisto-
chemical procedures were done as described previously [13]. For the
quantification of MVD, 10 random 0.159-mm2 fields at a magnifi-
cation of ×100 were captured, and CD31-positive cells were quanti-
fied according to a method described previously [12]. Analysis of
apoptotic cells was done by using a commercially available TUNEL
kit (Promega, Madison, WI). To quantify the apoptotic index, the
TUNEL-positive cells were counted in 10 random 0.159-mm2 fields
at a magnification of ×100.
Double Immunofluorescence Staining for CD31 and TUNEL
Frozen sections of cecal tumors were used for assay. Specimens
were cut into 4-μm sections, mounted on positively charged slides,
and stored at −80°C. Slides were fixed in cold acetone for 10 min-
utes, placed in a light-shielded humidified chamber, incubated with
protein blocking solution (5% normal horse serum and 1% normal
goat serum in PBS) for 20 minutes at room temperature, and incu-
bated overnight at 4°C with primary antibody against CD31 (1:800).
The slides were washed with PBS three times and then incubated
for 1 hour at room temperature with goat anti–rat Cy3 secondary
antibody (1:500). Then, TUNEL assay was done by using a com-
mercially available TUNEL kit. Nuclear counterstain with Sytox
green was applied for 10 minutes, and slides were covered with a
glass coverslip (Fischer Scientific) as described in the above para-
graphs. TUNEL-positive apoptotic cells were detected by localized
green fluorescence within the cell nuclei, and endothelial cells
(CD31-positive cells) were identified by red fluorescence. Apoptotic
endothelial cells were detected by colocalization of red and green
fluorescence, which appeared yellow, within the nuclei. The total
number of apoptotic cells was quantified in 10 randomly selected
microscopic fields and expressed as the ratio of apoptotic endothelial
cells to the total number of endothelial (magnification, ×400).
Confocal Microscopy
Confocal fluorescence images were obtained by using ×20 or ×40
objectives on a laser scanning microscope (LSM 510; Carl Zeiss Inc.,
Thornwood, NY) equipped with a motorized Axioplan microscope,
argon laser (458/477/488/514 nm, 30 mW), HeNe laser (543 nm,
1 mW and 633 nm, 5 mW), LSM 510 control and image acquisi-
tion software, and appropriate filters (Chroma Technology Corp.,
Brattleboro, VT). Confocal images were exported to Adobe Photo-
shop software, and montages were prepared.
Statistical Analysis
We used the Mann-Whitney U test to compare the body weight of
mice, tumor weight, the number of Ki-67–positive cells, the MVD
(CD31/PECAM-1), and the number of TUNEL-positive cells.
Results
Expression of TGF-α and EGFR in SW620CE2 Parent,
SW620CE2 Nontargeting shRNA, and SW620CE2
TGF-α shRNA Human Colon Carcinoma Cells In Vitro
In the first set of experiments, we examined the expression of
TGF-α in SW620CE2 parent, SW620CE2 nontargeting shRNA,
and SW620CE2 TGF-α shRNA cells growing in culture by RT-
PCR and ELISA (Figure 1, A and B). SW620CE2 parent cells and
SW620CE2 nontargeting shRNA cells expressed high levels of
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TGF-α. The expression of TGF-α by SW620CE2 TGF-α shRNA
cells was reduced by more than 80%. Because immunohistochemistry
as a single parameter may not determine absolute presence or absence
of the EGFR on colon cancer cells [34], we also examined the in vitro
expression of EGFR by RT-PCR and Western blot analysis (Figure 1,
C and D). SW620CE2 parent, SW620CE2 nontargeting shRNA, and
SW620CE2 TGF-α shRNA cells expressed minimal levels of EGFR
protein or mRNA. HT29 human colon carcinoma cells [26,27] used
as a positive control expressed high levels of EGFR. The SW620CE2
cells do not express the VEGFR2 but do express VEGFA. Transduc-
tion with nontargeting shRNA or TGF-α shRNA did not change
these properties (Figure 1).
Treatment of SW620CE2 WT, SW620CE2 Nontargeting
shRNA, or SW620CE2 TGF-α shRNA Human Colon
Cancer Cells Growing in the Cecum of Nude Mice
In the next set of experiments, we determined the therapeutic
effects of PKI166, irinotecan, or the combination of PKI166 and
irinotecan, and the growth and metastasis of SW620CE2 WT,
SW620CE2 nontargeting shRNA, or SW620CE2 TGF-α shRNA
human colon cancer cells growing in the cecum of nude mice (ortho-
topic animal model). Tumor cells were injected into the cecal wall of
nude mice. Treatment began 2 weeks later when the tumors were
established. After 5 weeks of treatment, all mice were euthanized
and necropsied. All three cell lines produced cecal tumors in all in-
jected mice (Table 1), suggesting that autocrine-paracrine loops of
TGF-α/EGFR are not required for tumor growth. None of the treat-
ments significantly affected body weight.
In mice injected with SW620CE2 WT tumors, control mice had
the largest tumors (median, 0.31 g; range, 0.14–0.46 g) (Table 1).
Mesenteric lymph node metastasis was found in 7 of 10 mice. Treat-
ment with only PKI166 significantly reduced the weight of cecal
tumors (median, 0.15 g; range, 0.09–0.31 g; P < .05, compared with
control). Three of 10 mice had lymph node metastasis. Treatment
with only irinotecan also inhibited tumor growth (median, 0.20 g;
range, 0.13–0.34 g; P < .05, compared with control). Lymph node
metastasis was found in 4 of 10 mice. Treatment with oral adminis-
tration of PKI166 and i.p. injection of irinotecan produced the most
significant inhibition of cecal tumor (median, 0.10 g; range, 0.04–
0.20 g; P < .001, compared with control and P < .05, compared with
irinotecan alone) and completely inhibited metastasis to regional
lymph nodes (P < .05, compared with control).
In mice injected with SW620CE2 nontargeting shRNA tumor
cells (Table 1), control mice had the largest tumors (median, 0.29 g;
range, 0.17–0.42 g), and 6 of 9 mice had metastasis in the regional
lymph nodes. Oral administration of PKI166 significantly reduced
the weight of the cecal tumors (median, 0.16 g; range, 0.08–0.28 g;
P < .05, compared with control) and decreased the incidence of lymph
node metastasis to 2 of 9 mice. Intraperitoneal injection of irinotecan
also inhibited cecal tumor growth (median, 0.19 g; range, 0.13–
0.25 g; P < .05, compared with control). Oral administration of
PKI166 and i.p. injection of irinotecan produced the most signifi-
cant inhibition of cecal tumor growth (median, 0.09 g; range, 0.04–
0.19 g; P < .001, compared with control and P < .05, compared with
irinotecan alone) and completely inhibited lymph node metastasis (P <
.05, compared with control). The results obtained with the SW620CE
Figure 1. The expression of TGF-α and EGFR by SW620CE2, SW620CE2 nontargeting shRNA, and SW620CE2 TGF-α shRNA cells grow-
ing in culture. RT-PCR (A), ELISA (B), and Western blot analysis (D) reveal that using the lentiviral system, the expression of TGF-α was
decreased in the SW620CE2 TGF-α shRNA cells compared to the other cells, SW620CE2 WT and SW620CE2 nontargeting shRNA cells
that expressed minimal levels of EGFR mRNA (C) and protein (D). HT29 human colon carcinoma cells [27] were used as the positive
control for EGFR expression.
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nontargeting shRNA were therefore similar to that obtained with the
SW620CE2 WT tumors.
In mice injected with SW620CE2 TGF-α shRNA tumor cells, the
control group had the largest cecal tumors (median, 0.24 g; range,
0.15–0.43 g), and 3 of 9 mice had lymph node metastasis (Table 1).
Oral administration of PKI166 did not produce significant changes in
tumor weight (median, 0.22 g; range, 0.13–0.35 g). Treatment with
irinotecan alone inhibited tumor growth (median, 0.15 g; range,
0.07–0.28 g; P < .05, compared with control). The weight of cecal
tumors in mice treated with the combination of oral PKI166 and
i.p. irinotecan was comparable to mice treated with only irinotecan
(median, 0.16 g; range, 0.05–0.24 g; P < .001). The incidence of
lymph node metastasis was higher in mice with SW620CE2 WT
and SW620CE nontargeting shRNA than in mice with SW620CE2
TGF-α shRNA cecal tumors.
Immunohistochemical Analysis
Next, we determined the expression of TGF-α, EGF, EGFR, and
phosphorylated EGFR (pEGFR) in tumors by immunohistochemical
analysis. SW620CE2 WT and SW620CE nontargeting shRNA
tumors expressed high levels of TGF-α, whereas the SW620CE2
TGF-α shRNA tumor did not (Figure 2). Because the immunohisto-
chemistry was carried out on cells transfected with the TGF-α shRNA
at least 12 weeks before the assay, the absence of TGF-α expression
verified the stability of the transfection. None of the tumors expressed
EGF (data not shown).
Dual localization of CD31 (green) and EGFR (red) or pEGFR (red)
confirmed that tumor cells in all three colon carcinoma groups did not
express the EGFR (and hence pEGFR). In all groups, tumor-associated
endothelial cells expressed the EGFR (yellow). In the SW620CE WT
tumors and SW620CE nontargeting shRNA treated with PKI166 or
PKI166 plus irinotecan, the EGFR was not phosphorylated. In the
SW620CE2 TGF-α shRNA tumor, tumor-associated endothelial cells
expressed EGFR (yellow) that was not phosphorylated (Figure 2).
Cell Proliferation (Ki-67), Apoptosis (TUNEL), and MVD
in Cecal Tumors
Cell proliferation was evaluated by staining for Ki-67 (Table 2).
In SW620CE2 WT tumors, the median number of Ki-67 LI of con-
trol group was 17 (range, 8–28). Treatment with irinotecan alone
or PKI166 alone significantly decreased the number of Ki-67 LI
(median, 11; range, 4–19 and median, 10; range, 4–20, respectively;
P < .05, compared with control). Treatment with both PKI166 and
irinotecan produced the most significant decrease in cell proliferation
(median, 6; range, 3–15; P < .01, compared with control). In
SW620CE2 nontargeting shRNA tumors, the median number of
Ki-67 LI of control group was 19 (range, 10–32). Treatment with
irinotecan alone or PKI166 alone significantly decreased the number
of Ki-67 LI (median, 10; range, 7–21 and median, 11; range, 6–22,
respectively; P < .05, compared with control). Treatment with both
PKI166 and irinotecan produced the most significant decrease in cell
proliferation (median, 7; range, 3–18; P < .01, compared with con-
trol). In SW620CE2 TGF-α shRNA tumors, the median number of
Ki-67 LI of control group was 14 (range, 9–24). The treatment with
irinotecan alone significantly decreased Ki-67 LI (median, 9; range,
4–18; P < .05, compared with control), whereas treatment with
Table 1. Therapy for SW620CE2, SW620CE2 Nontargeting shRNA, and SW620CE2 TGF-α shRNA Tumors Growing in the Cecal Wall of Nude Mice.
Body Weight (g), Median (Range) Tumor Incidence Tumor Weight (g), Median (Range) Incidence of Lymph Node Metastasis
WT Control 30.7 (27.5–33.6) 10/10 0.31 (0.14–0.46) 7/10
Irinotecan 31.5 (28.2–35.2) 10/10 0.20 (0.14–0.46)* 4/10
PKI166 30.2 (28.2–35.2) 10/10 0.15 (0.09–0.31)* 3/10
PKI166/Irinotecan 30.4 (27.5–33.9) 10/10 0.10 (0.04–0.20)†,‡ 0/10
Nontargeting shRNA Control 31.3 (27.1–35.3) 9/9 0.29 (0.17–0.42) 6/9
Irinotecan 32.0 (27.6–33.9) 10/10 0.19 (0.13–0.25)* 5/10
PKI166 31.5 (28.0–33.6 9/9 0.16 (0.08–0.28)* 2/9
PKI166/Irinotecan 30.4 (27.3–33.5) 10/10 0.09 (0.04–0.19)†,‡ 0/10
TGF-α Control 31.7 (27.8–33.4) 9/9 0.24 (0.15–0.43) 3/9
Irinotecan 31.5 (27.8–33.4) 10/10 0.15 (0.07–0.28)* 2/10
PKI166 30.4 (27.5–31.7) 10/10 0.22 (0.13–0.35) 3/10
PKI166/Irinotecan 30.9 (27.5–32.7) 10/10 0.16 (0.05–0.24)* 2/10
*P < .05, compared with control group.
†P < .001, compared with control group.
‡P < .05, compared with irinotecan group.
Figure 2. Immunohistochemical analysis of the expression of SW620CE2 WT, SW620CE2 nontargeting shRNA and SW620CE2 TGF-α
shRNA cells growing in the cecum of nude mice. Human colon cancer cells were implanted into the cecum of nude mice. Two weeks
later, treatment with saline (control), irinotecan (CPT-11; 10 mg/kg, i.p. injection, once per week), PKI166 (100 mg/kg, p.o., three times
per week), or PKI166 and irinotecan began. Five weeks later, the mice were euthanized and autopsied. Cecal tumors were resected and
fixed in buffered formalin or embedded in optimal cutting temperature compound for frozen sections. Paraffin-embedded tissues were
processed for immunohistochemical analysis of TGF-α. SW620CE2 WT and SW620CE2 nontargeting shRNA tumor cells expressed
TGF-α, whereas SW620CE2 TGF-α shRNA tumor cells did not. Treatment with irinotecan alone, PKI166 alone, or the combination of
PKI166 and irinotecan did not alter the expression level of TGF-α. Frozen sections were used for double immunofluorescence staining
for CD31 (green) and EGFR or pEGFR (red). Colocalization of CD31 and EGFR or pEGFR produces yellow fluorescence. EGFR and pEGFR
were not expressed in any of the tumor cells. In contrast, most tumor-associated endothelial cells from all the groups expressed high
level of EGFR. The phosphorylation of EGFR was diminished on tumor-associated endothelial cells from SW620CE2 WT and SW620CE2
nontargeting shRNA tumors from mice treated with PKI166 alone or PKI166 and irinotecan. In contrast, the EGFR on tumor-associated
endothelial cells from any of the SW620CE2 TGF-α shRNA tumors were not phosphorylated.
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PKI166 alone did not. Treatment of mice with both PKI166 and
irinotecan produced the same results as irinotecan administered alone
(median, 8; range, 4–16; P < .05, compared with control).
The induction of apoptosis in the tumors at the end of 5 weeks of
treatment was determined by the TUNEL assay (Figure 3). In con-
trol mice injected with SW620CE2 WT cells, the median number of
apoptotic tumor cells was 1 (range, 0–4). Treatment with irinotecan
alone or PKI166 alone significantly increased the number of apopto-
tic tumor cells (median, 6; range, 1–18 and median, 9; range, 1–22,
respectively; P < .05, compared with control). The most significant
induction of apoptosis was observed in tumors in from mice treated
with both PKI166 and irinotecan (median, 15; range, 4–28; P <
.001, compared with control) (Table 2). In the SW620CE2 non-
targeting shRNA tumors, the median number of apoptotic tumor
cells in control treatment group was 1 (range, 0–4). Treatment with
irinotecan alone or PKI166 alone increased the number of apop-
totic tumor cells (median, 5; range, 1–16 and median, 7; range,
2–19; respectively; P < .05, compared with control). Similar to the
SW620CE2 WT tumors, the most significant induction of apop-
tosis was produced by the combination treatment of PKI166 and
irinotecan (median, 17; range, 3–26; P < .001, compared with con-
trol) (Table 2).
In control mice injected with SW620CE TGF-α shRNA cells and
treated with saline, the median number of apoptotic tumor cells was
1 (range, 0–3). Treatment with irinotecan significantly increased the
number of apoptotic tumor cells (median, 5; range, 1–14; P < .05,
Table 2. Immunohistochemical Analysis of SW620CE2 Human Colon Cancer Cells Treated with TGF-α shRNA or Nontargeting shRNA Growing in the Cecal Wall of Nude Mice.
Tumor Cells Endothelial Cells
Ki-67 LI TUNEL MVD TUNEL
WT Control 17 (8–28) 1 (0–4) 48 (28–73) 0 (0–3)
Irinotecan 11 (4–19)* 6 (1–18)* 43 (27–60) 1 (0–6)
PKI166 10 (4–20)* 9 (1–22)* 16 (7–25)† 6 (0–11)*
PKI166/Irinotecan 6 (3–15)*,‡ 15 (4–28)†,‡ 11 (5–28)†,‡ 8 (0–19)*,‡
Nontargeting shRNA Control 19 (10–32) 1 (0–4) 43 (28–70) 0 (0–4)
Irinotecan 10 (7–21)* 5 (1–16)* 40 (22–72) 1 (0–55)
PKI166 11 (6–22)* 7 (2–19)* 15 (8–32)† 7 (0–18)*
PKI166/Irinotecan 7 (3–18)*,‡ 17 (3–26)†,‡ 12 (5–22)†,‡ 8 (0–14)*,‡
TGF-α shRNA Control 14 (9–24) 1 (0–3) 39 (22–62) 0 (0–4)
Irinotecan 9 (4–18)* 5 (1–14)* 36 (21–59)* 1 (0–5)
PKI166 12 (7–25) 1 (0–4) 35 (18–49) 1 (0–5)
PKI166/Irinotecan 8 (4–16)* 6 (1–19)* 33 (20–52)* 2 (0–6)
*P < .05, compared with control group.
†P < .001, compared with control group.
‡P < .05, compared with irinotecan group.
Figure 3. Analysis of apoptosis of tumor cells and tumor-associated endothelial cells. Cecal tumors from different treatment groups
were analyzed by immunohistochemistry for apoptosis (TUNEL). In control mice injected with SW620CE TGF-α shRNA cells, treatment
with irinotecan (CPT-11) significantly increased the number of apoptotic cells. Note that in SW620CE and SW620CE nontargeting shRNA
tumors, treatment with irinotecan or PKI166 increased the number of apoptotic cells. Treatment with both irinotecan and PKI166 pro-
duced additive effects. In the SW620CE TGF-α shRNA neither the CPT-11 nor the PKI166 produced significant apoptosis.
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compared with control), whereas treatment with only PKI166 did
not (Figure 3). Treatment with both PKI166 and irinotecan pro-
duced the same induction of apoptosis as irinotecan (median, 6;
range, 1–19; P < .05, compared with control).
Microvessel Number and Apoptosis of Endothelial Cells in
Cecal Tumors
MVD was determined by staining for CD31 (Figure 4A; Table 2).
In SW620CE2 WT tumors from mice treated with saline, the median
number of MVD was 48 (range, 28–73). Treatment with irinotecan
did not change the MVD. Treatment with PKI166 alone significantly
decreased the number of microvessels (median, 16; range, 7–25;
P < .001, compared with control). Treatment with both PKI166
and irinotecan also produced a significant decrease of vessels (median,
11; range, 5–28; P < .001, compared with control). In SW620CE2
nontargeting shRNA tumors from mice treated with saline (control),
the median number of microvessels was 43 (range, 28–70). Treatment
with irinotecan did not decrease the MVD. Treatment with PKI166
alone significantly decreased the number of MVD (median, 15; range,
8–32; P < .001, compared with control). Treatment with PKI166 and
irinotecan also produced significant decrease in the MVD (median,
12; range, 5–22; P < .001, compared with control). In SW620CE2
TGF-α shRNA tumors from mice treated with saline, the median
number of microvessels was 39 (range, 22–62). Treatment with irino-
tecan alone, PKI166 alone, or combination of PKI166 and irinotecan
Figure 4. Analysis for MVD. (A) MVD was determined by staining for CD31. In SW620CE2 WT and SW620CE2 nontargeting shRNA
tumors, treatment with PKI166 alone and with PKI166 and irinotecan (CPT-11) significantly decreased the number of MVD. In SW620CE2
TGF-α shRNA tumors, treatment with PKI166 alone, irinotecan alone, or the combination of PKI166 and irinotecan did not significantly
decreased the number of MVD. (B) Apoptosis of endothelial cells was determined by double staining for CD31 (red) and TUNEL (green).
In cecal tumors produced by SW620CE2 WT and SW620CE2 nontargeting shRNA cells, treatment with PKI166 and irinotecan produced
apoptosis in tumor-associated endothelial cells. None of the treatments induced apoptosis in tumor-associated endothelial cells of the
SW620CE TGF-α tumors.
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did not produce a significant decrease in the MVD (median, 36; range,
21–59; median, 35; range, 18–49; and median, 33; range, 20–52, re-
spectively; P > .05, compared with control).
Apoptosis of endothelial cells was determined by double staining for
CD31 (red) and TUNEL (green) (Figure 4B; Table 2). In SW620CE2
WT tumors from control mice, the median number of apoptotic
endothelial cells was 0 (range, 0–3). Treatment with irinotecan did
not produce apoptosis in endothelial cells. Treatment with PKI166
alone significantly increased the number of apoptotic endothelial cells
(median, 6; range, 0–11; P < .05, compared with control).
Treatment with both PKI166 and irinotecan (median, 8; range, 0–
19; P < .05, compared with control) also produced significant increase
in apoptosis of tumor-associated endothelial cells. In SW620CE2 non-
targeting shRNA tumors, the median number of apoptotic endothelial
cells in control tumors was 0 (range, 0–4). Treatment with PKI166
alone significantly increased the number of apoptotic endothelial cells
(median, 7; range, 0–18; P < .05, compared with control) also did the
combination of PKI166 and irinotecan (median, 8; range, 0–14; P <
.05, compared with control). In SW620CE2 TGF-α shRNA tumors
from mice treated with saline (control), the median number of apop-
totic endothelial cells was 0 (range, 0–4). Treatment with irinotecan
alone, PKI166 alone, or the combination of PKI166 and irinotecan
did not produce a significant increase in apoptosis of tumor-associated
endothelial cells (median, 1; range, 0–5; median, 1; range, 0–5; and
median, 2; range, 0–6, respectively; P > .05, compared with control).
Discussion
We here present compelling evidence to support the important
role of paracrine activation of EGFR in tumor-associated endothelial
cells in the colon for mediating response to EGFR kinase inhibi-
tors. In the current study, we report that the systemic administra-
tion of the EGFR-TKI PKI166 to nude mice bearing the human
SW620CE2 colon cancer leads to significant inhibition of cecal
tumor growth and lymph node metastasis. The SW620CE2 cells
do not express EGFR, HER2, or VEGFR but do express the EGFR
ligands TGF-α/EGF. Colon tumors produced by SW620CE2 cells
treated with TGF-α shRNA were resistant to PKI166. The expres-
sion of activated EGFR by tumor-associated endothelial cells is influ-
enced by the production of TGF-α/EGF by adjacent tumor cells
[25–27,35,36] and immunohistochemical analyses of the orthotopic
colon tumors revealed that tumor-associated endothelial cells in
SW620CE2 tumors (TGF-α+) expressed activated EGFR, whereas
tumor-associated endothelial cells in SW620CE2 TGF-α shRNA
(TGF-α−) did not. Therapy with PKI166 and irinotecan produced
additive apoptosis of tumor-associated endothelial cells in the
SW620CE2 cecal tumors (TGF-α+) but not in the SW620CE2
TGF-α shRNA (TGF-α−) cecal tumors. The apoptosis of tumor-
associated endothelial cells was associated with a significant inhibition
in cecal tumor growth and production of lymph node metastasis. Be-
cause neither set of tumors expressed EGFR or HER-2, the data clearly
indicate that the susceptibility of the human colon cancer SW620CE2
to therapy by EGFR-TKI is determined by expression of ligand TGF-
α/EGF and that the primary target for therapy with the EGFR-TKI is
the tumor-associated endothelial cells.
The response of neoplasms to EGFR antagonists has been cor-
related with EGFR mutations, HER2 expression, Akt activation
[21,23,24], and EGFR gene copy number [24,37]. Our present data
using colon cancer cells that do not express EGFR, HER2, or
VEGFR suggest that the expression of TGF-α/EGF by tumor cells
leading to the activation of the EGFR in tumor-associated endothe-
lial cells is a major determinant for response. These data agree with a
previous report that human renal cancer that express TGF-α with
activated EGFR in tumor-associated endothelial cells respond to
treatment by PKI166 [35]. Recent studies report that pancreatic
[26], colon [27], prostate [38], ovarian [39], and head and neck
[40] neoplasms that express wild-type EGFR and TGF-α/EGF lead-
ing to activation of EGFR in tumor-associated endothelial cells re-
spond to treatment with TKI. Moreover, retrospective analysis of a
recent clinical trial of cetuximab (Erbitux, a chimeric monoclonal
anti-EGFR antibody) showed that colorectal cancer patients with
EGFR-negative tumors could respond to therapy [41]. These results
have been confirmed in other clinical studies [42] and are also con-
sistent with recent preclinical studies using cetuximab showing that
the activity of the agent was unrelated to relative total or activated
EGFR expression levels [43]. Collectively, these data recommend
that predicting response of individual neoplasms to EGFR-TKI
can be best accomplished by careful screening of biopsy specimen
for expression of the ligand TGF-α/EGF and phosphorylated EGFR
in tumor cells and especially in tumor-associated endothelial cells.
The progressive growth, survival, and metastasis of neoplasms de-
pend on the development and maintenance of an adequate vascular
supply [44]. Specifically, the survival of all cells in the body depends
on an adequate supply of nutrients and oxygen and removal of waste
products, i.e., vascular supply [3,45]. Because the genetic instability
of neoplastic cells in general and metastatic cells in particular leads to
the generation of biologic heterogeneity in neoplasms, targeting the
neovasculature of neoplasms has been explored as an approach to
therapy [1,46,47]. Antivascular therapy can destroy tumor cells that
require nutrients and oxygen for survival. Endothelial cells in normal
tissues rarely divide, whereas up to 2% to 5% of endothelial cells in
neoplasms divide daily [48]. These dividing endothelial cells should
be sensitive to anticycling drugs, such as irinotecan [3]. However, the
major signaling pathways induced by activation of tyrosine kinase
receptors are Akt and P13K, which can affect not only cell prolifera-
tion but also inhibition of apoptosis [49,50]. In our study, inhibition
of EGFR activation on tumor-associated endothelial cells by PKI166
inhibited the dividing endothelial cells’ resistance to irinotecan and
therefore induced their apoptosis leading to a marked decrease in
microvessel density, decreased proliferation of tumor cells, and in-
creased apoptosis of tumor cells. These differences between dividing
tumor-associated endothelial cells and quiescent endothelial cells in
normal tissues [48] allow selective therapy with EGFR-TKI com-
bined with chemotherapy. Our results may provide an explanation
as to why suppression of proliferation of EGFR-positive tumor cells
by EGFR targeting drugs—which should render the treated cancer less
susceptible to chemotherapy drugs—can lead to increased chemo-
sensitivity. If the primary targets are EGFR-positive tumor-associated
endothelial cells, the proliferative status of the tumor cell population
may be irrelevant to the effects of the chemotherapy obtained.
Many investigators undertaking clinical trials of EGFR-TKI have
ignored the possibility that tumor-associated endothelial cells can be
a major target of TKIs of the EGFR. Thus, based on our current
findings, we suggest that the clinical use of TKI specific to EGFR
will be more effective against neoplasms that express high levels of
TGF-α/EGF. In these tumors, destruction of tumor-associated endo-
thelial cells should lead to apoptosis of adjacent tumor cells and stro-
mal cells leading to necrosis of primary neoplasms and metastases.
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